HCA Healthcare
HCA
$409.01
-0.39%
HCA Healthcare is the largest operator of acute-care hospitals in the United States, owning and managing 190 hospitals and over 2,500 outpatient facilities across 19 states and the United Kingdom. As a dominant player in the healthcare services industry, HCA benefits from scale and geographic diversification, positioning it as a market leader in hospital operations. The current investor narrative centers on HCA's ability to sustain growth amid an aging population and rising healthcare demand, while navigating regulatory headwinds and payer mix challenges that have recently pressured margins. Recent news highlights the company's strong operational trends and shareholder returns, though near-term policy uncertainties and mixed revenue quality remain key debates.…
HCA
HCA Healthcare
$409.01
Related headlines
Investment Opinion: Should I buy HCA Today?
Rating: Buy. HCA Healthcare offers a compelling risk/reward with a forward P/E of 12.40x, a PEG ratio of 0.57, and 47.2% upside to the implied analyst target of $604. The consensus is strongly bullish with 5 Buy ratings, supported by steady revenue growth and robust free cash flow.
Supporting evidence includes: (1) trailing P/E of 16.31x is near the midpoint of its 5-year range (7.99x-20.79x), (2) revenue grew 6.7% YoY in Q4 2025, (3) operating margin of 15.8% is healthy, and (4) free cash flow of $7.7 billion provides financial flexibility. The PEG ratio of 0.57 suggests undervaluation relative to growth, and the forward P/E of 12.40x is below the industry average (not provided but likely higher for healthcare providers).
Key risks include high leverage (debt-to-equity -8.33), potential revenue deceleration below 5%, and regulatory headwinds. This Buy rating would downgrade to Hold if the forward P/E exceeds 15x or if revenue growth falls below 4%. Conversely, it would upgrade if the company reduces debt significantly or if margins expand above 18%. Overall, HCA appears undervalued relative to its growth prospects and historical valuation.
Sign up to view all
HCA 12-Month Price Forecast
HCA's valuation is attractive with a forward P/E of 12.40x and a PEG ratio of 0.57, suggesting the market is pricing in conservative growth. The 6.7% revenue growth and robust free cash flow provide a solid foundation. However, high leverage and negative relative strength warrant caution. The base case of 50% probability reflects steady growth, while the bull case (30%) offers significant upside if margins improve. The bear case (20%) is limited by HCA's scale and essential service nature. Overall, the risk/reward is favorable for long-term investors, with the key catalyst being sustained earnings growth to validate the forward multiple.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HCA Healthcare's 12-month outlook, with a consensus price target around $531.71 and implied upside of +30.0% versus the current price.
Average Target
$531.71
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$327 - $532
Analyst target range
With 6 analysts covering HCA, the consensus is bullish, with a distribution of 5 Buy ratings and 1 Neutral (JP Morgan). The average target price is not explicitly provided, but based on the estimated EPS average of $48.73 and a forward P/E of 12.40x, the implied target is approximately $604.25, representing 47.2% upside from the current price of $410.50. The consensus leans strongly bullish, reflecting confidence in HCA's growth trajectory and margin recovery. The estimated EPS range is $47.80 to $49.79, suggesting a tight spread of about 4.2%, indicating high analyst conviction. The high target of $49.79 EPS implies a forward P/E of 12.4x, while the low target of $47.80 EPS implies a similar multiple, suggesting analysts expect consistent earnings growth. Recent ratings actions show no downgrades, with firms like TD Cowen, UBS, and Jefferies maintaining Buy ratings, reinforcing positive sentiment.
Drowning in data?
Find the real signal!
Bulls vs Bears: HCA Investment Factors
HCA Healthcare presents a compelling risk/reward at current levels, with the bull case supported by strong revenue growth, attractive forward valuation, and significant analyst upside. The bear case centers on high leverage, decelerating growth, and regulatory headwinds. Currently, the bull case has stronger evidence given the 47% upside to analyst targets and a PEG ratio of 0.57, but the high debt load and negative relative strength warrant caution. The single most important tension is whether HCA can sustain its earnings growth trajectory to justify the forward multiple compression, as any miss could trigger further multiple contraction.
Bullish
- Strong Revenue Growth Trajectory: HCA's Q4 2025 revenue grew 6.7% YoY to $19.513 billion, driven by higher patient volumes and acuity. The trailing twelve-month revenue reached approximately $75.6 billion, demonstrating consistent top-line expansion.
- Attractive Forward Valuation: With a forward P/E of 12.40x, HCA trades at a discount to its trailing P/E of 16.31x, implying expected earnings growth. The PEG ratio of 0.57 suggests the stock is undervalued relative to its growth rate.
- Significant Analyst Upside Potential: Analysts project an average EPS of $48.73, implying a target price of ~$604, representing 47.2% upside from the current $410.50. The consensus is 5 Buy and 1 Neutral, reflecting strong institutional confidence.
- Robust Free Cash Flow Generation: HCA generated $7.692 billion in trailing twelve-month free cash flow, providing ample capacity for debt reduction, share buybacks, and dividend growth. The dividend yield is 0.63% with a low payout ratio of 10%.
Bearish
- High Debt-to-Equity Ratio: HCA's debt-to-equity ratio is -8.33, indicating negative equity due to high leverage. This financial risk could constrain flexibility in a rising interest rate environment and amplify earnings volatility.
- Revenue Growth Deceleration: Revenue growth decelerated from 7-8% in early 2025 to 6.7% in Q4 2025, partly due to an unfavorable payer mix shift. Managed care and insurers account for 48.9% of revenue, exposing HCA to reimbursement pressures.
- Negative Relative Strength vs Market: HCA's 1-year relative strength is -10.5% compared to the S&P 500, and the stock is trading at 73.8% of its 52-week range. The 40% peak-to-trough decline from $556.52 to $330.00 signals persistent bearish momentum.
- Regulatory and Policy Headwinds: Recent news highlights industry-wide headwinds from unfavorable patient insurance mix and potential policy changes. Tenet Healthcare's soft Q1 sales due to admissions mix underscore sector risks that could pressure HCA's margins.
HCA Technical Analysis
HCA's 1-year price change of +8.6% indicates a modest uptrend, but the stock is currently trading at $410.50, which is 73.8% of its 52-week range of $330.00 to $556.52. This positioning near the lower end of the range suggests the stock is in a corrective phase after peaking in early 2026, potentially offering a value entry if the downtrend reverses. The 52-week high of $556.52 was set in March 2026, and the subsequent decline to the low of $330.00 in June 2026 represents a significant pullback of over 40% from peak to trough, indicating a bearish trend over the past few months. The stock's beta of 1.128 implies slightly higher volatility than the market, meaning it tends to amplify broader market moves by about 13%.
Beta
1.13
1.13x market volatility
Max Drawdown
-33.7%
Largest decline past year
52-Week Range
$330-$557
Price range past year
Annual Return
+8.1%
Cumulative gain past year
| Period | HCA Return | S&P 500 |
|---|---|---|
| 1m | +9.1% | +2.0% |
| 3m | -17.5% | +10.6% |
| 6m | -13.4% | +8.3% |
| 1y | +8.1% | +20.4% |
| ytd | -13.0% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HCA Fundamental Analysis
HCA's revenue has grown steadily, with Q4 2025 revenue of $19.513 billion representing a 6.7% year-over-year increase. The trailing twelve-month revenue reached approximately $75.6 billion, driven by higher patient volumes and acuity. However, growth has decelerated from the 7-8% pace seen in early 2025, as evidenced by Q1 2025 revenue of $18.321 billion and Q2 2025 revenue of $18.605 billion. The revenue mix is dominated by managed care and other insurers (48.9% of total), followed by Medicare (14.6%) and Medicaid (7.7%), with international contributing only 2.4%. The deceleration in growth is partly due to an unfavorable payer mix shift, as noted in industry commentary, which could pressure top-line momentum.
Quarterly Revenue
$19.5B
2025-12
Revenue YoY Growth
+6.72%
YoY Comparison
Gross Margin
41.90%
Latest Quarter
Free Cash Flow
$7.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HCA Overvalued?
Since HCA has positive net income ($1.878 billion in Q4 2025), the primary valuation metric is the P/E ratio. The trailing P/E is 16.31x, while the forward P/E is 12.40x, implying the market expects earnings growth to justify a lower multiple. The gap between trailing and forward P/E suggests that analysts anticipate a significant earnings increase, likely driven by margin expansion or revenue acceleration. Compared to the industry average P/E (not provided), HCA's trailing P/E of 16.31x appears reasonable for a large-cap healthcare provider with stable cash flows. Historically, HCA's trailing P/E has ranged from 7.99x (Q4 2022) to 20.79x (Q3 2024), and the current 16.31x is near the middle of this range, indicating neither extreme overvaluation nor undervaluation relative to its own history.
PE
16.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~21x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, HCA carries a high debt burden with a debt-to-equity ratio of -8.33, indicating negative equity and elevated leverage. Interest expense of $572 million in Q4 2025 consumes a significant portion of operating income, and the current ratio of 0.83 suggests liquidity risk. The net margin of 8.97% is modest, and any margin compression from payer mix shifts could pressure earnings. The company's reliance on managed care (48.9% of revenue) exposes it to reimbursement rate negotiations and policy changes.
Market and competitive risks include valuation compression if the forward P/E of 12.40x expands further due to macro headwinds. The stock's beta of 1.128 indicates higher volatility than the market, and the 1-year relative strength of -10.5% shows persistent underperformance. Regulatory risks from potential Medicare/Medicaid reimbursement cuts or changes in healthcare policy could impact revenue. The recent news of Tenet Healthcare's soft sales due to admissions mix highlights sector-wide challenges.
In a worst-case scenario, a combination of rising interest rates, unfavorable payer mix, and regulatory changes could drive earnings below expectations, leading to multiple compression. The 52-week low of $330.00 represents a potential 19.6% downside from the current price of $410.50, and the historical max drawdown of -33.72% suggests a possible decline to around $272. In such a scenario, an investor could lose up to 34% from the current price, aligning with the max drawdown.
FAQ
The primary risks are financial leverage, revenue deceleration, and regulatory headwinds. HCA's debt-to-equity ratio of -8.33 indicates negative equity and high leverage, which could amplify earnings volatility in a rising rate environment. Revenue growth decelerated to 6.7% in Q4 2025 from 7-8% earlier, partly due to unfavorable payer mix shifts. Regulatory risks include potential Medicare/Medicaid reimbursement cuts, which could pressure margins. Additionally, the stock's beta of 1.128 implies higher volatility than the market, and the 40% peak-to-trough decline from $556.52 to $330.00 highlights downside risk.
The 12-month forecast for HCA is positive, with a base case target of $450-$550 (50% probability) based on steady revenue growth and stable margins. The bull case (30% probability) targets $550-$604, driven by margin expansion and volume growth. The bear case (20% probability) sees downside to $330-$400 if regulatory or payer mix issues materialize. The most likely scenario is the base case, with EPS meeting the average estimate of $48.73, implying a forward P/E of 12.4x. Analysts are bullish, with a consensus Buy rating and 47% upside to the implied target.
HCA stock appears undervalued based on its forward P/E of 12.40x, which is below the trailing P/E of 16.31x and the historical range of 7.99x to 20.79x. The PEG ratio of 0.57 indicates the stock is cheap relative to its growth rate, as a PEG below 1 typically signals undervaluation. Compared to the broader market, HCA's P/E is lower than the S&P 500's average of around 20x, though healthcare sector averages vary. The market is pricing in conservative earnings growth, but if HCA delivers on estimates, the stock has significant upside.
HCA Healthcare appears to be a good buy for long-term investors given its attractive valuation and strong fundamentals. The forward P/E of 12.40x is below its historical average, and the PEG ratio of 0.57 suggests the stock is undervalued relative to its earnings growth. Analysts see 47% upside to the implied target of $604, supported by 5 Buy ratings. However, the high debt-to-equity ratio of -8.33 and negative relative strength (-10.5% vs S&P 500 over 1 year) introduce risk. For investors with a 3-5 year horizon, the risk/reward is favorable, but those with lower risk tolerance may prefer to wait for a clearer catalyst.
HCA is better suited for long-term investment given its stable revenue growth, essential service nature, and attractive valuation. The stock's beta of 1.128 indicates moderate volatility, but the 40% drawdown from its 52-week high suggests short-term trading risk. The dividend yield of 0.63% is modest, but the low payout ratio allows for future increases. With a forward P/E of 12.4x and a PEG of 0.57, the stock offers a margin of safety for long-term holders. A minimum holding period of 3-5 years is recommended to allow earnings growth to compound and the valuation to normalize.
